期刊文献+

硫酸铵梯度法制备伊立替康脂质体及稳定性研究 被引量:4

Preparation of Irinotecan Liposome by Ammonium Sulfate Gradient Method and Study on its Stability
下载PDF
导出
摘要 目的:制备盐酸伊立替康脂质体并考察提高脂质体稳定性的方法。方法:采用硫酸铵梯度法制备盐酸伊立替康脂质体。以粒径、外观、颜色、渗漏率作为指标,考察盐酸伊立替康脂质体的物理和化学稳定性。结果:硫酸铵梯度法制备的盐酸伊立替康脂质体呈圆球形,平均粒径为600nm,稳定性较好。结论:盐酸伊立替康脂质体不耐高温,将其制成冻干粉剂可显著提高药物稳定性。 Objective: To prepare Irinotecan liposomes and study its stability. Method: Ammonium sulfate gradient method was used to prepare Irinotecan liposomes, size of liposome, appearance, color, oxidation index were observed as indexes, Irinotecan liposome physical and chemical stability was inspected. Result: The average particle size of the liposomes were 600 nm in a pellet shape with a good stability. Conclusion : Irinotecan liposomes can not bear high temperature. Freeze-dried liposome can obviously improve its stability.
出处 《中国药师》 CAS 2008年第1期72-74,共3页 China Pharmacist
关键词 盐酸伊立替康 脂质体 稳定性 冻干脂质体 Irinotecan liposome stability freeze-dried liposome
  • 相关文献

参考文献5

二级参考文献51

  • 1Cersosmio RJ. Irinotecan: a new antineoplastic agent for the management of colorectal cancer[J].Ann Pharmacother,1998, 32(12) :1324 - 1333.
  • 2Rivory LP, Chatelut E; Canal P ,et al. Kinetics of the in vivo inter-conversion of the carboxylatee and lactone forms of irinoteacan (CPT-11) and of its metabohte SN-38 in patients[J]. Cancer Res,1994, 54(24):6330-6333.
  • 3Ratain MJ. Insights into the phamacokinetics and pharmacodynamics of irinotecan[J]. Clin Cancer Res. 2000, 6(9) : 3393 - 3394.
  • 4De Bruijn P, Verweij J,Loos WJ,et al.Determination of irinotecan(CPT-11 )and its active metabolite SN-38 in human plasma by reversed-phase high-performance liquid chromatography with fluorescence detection[J]. Chromatogr B Biomed Sci Appl, 1997, 698 ( 1/2 ) : 277-228.
  • 5Escoriaza J, Aldaz A, Castellanos C,et al. Simple and rapid determination of irinotecan and its metabolite SN-38 in plasma by high-performance liquid Chromatography: application to clinical pharmacokinetic studies[J]. J Chromatogr B Biomed Sci Appl . 2000. 740(2) :159-168.
  • 6Ragot S, Marquet P, Lachatre F,et al.Sensitive determination of irinotecan (CVF-11) and its active metabolite SN-38 in human serum using liquid chromatography-electrospray mass spectrometry [ J]. J Chromatogr B Biomed Sci Appl,1999, 7.36(1/2) : 175 - 184.
  • 7Saita T, Fujito H, Mori M. Development of ELISAs for irinotecan and its active metabolite SN-38[J].Biol Pharm Bull, 2000, 23(8):911-916.
  • 8Chabot GG, Abrigerges D, Catimel G et al. Population pharmacokinetics and pharmacodynamics of irinotecan(CPT-11) and active metabolite SN-38 during phase Ⅰ trials[J]. Arm Oncol, 1995, 6(2) : 141 - 151.
  • 9Ma MK, McLeod HL.Lessons learned from the metabolic pathway[J]. Curr Med Chem, 2003, 10(1):41 - 49.
  • 10Ando Y, Saka H, Ando M, et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis[J]. Cancer Res, 2000, 60(24):6921 -6926.

共引文献465

同被引文献54

引证文献4

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部